Portal de Periódicos da CAPES

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

2019; Nature Portfolio; Volume: 5; Issue: 1 Linguagem: Inglês

10.1038/s41523-019-0130-x

2374-4677

David B. Page, Harry D. Bear, Sangeetha Prabhakaran, Margaret E. Gatti‐Mays, Alexandra Thomas, Erin F. Cobain, Heather L. McArthur, Justin M. Balko, Sofia R. Gameiro, Rita Nanda, James L. Gulley, Kevin Kalinsky, Julia White, Jennifer K. Litton, Steven J. Chmura, Mei‐Yin C. Polley, Benjamin G. Vincent, David W. Cescon, Mary L. Disis, Joseph A. Sparano, Elizabeth A. Mittendorf, Sylvia Adams,

CAR-T cell therapy research

Abstract Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.